On the morning of November 5, the signing ceremony for the 2025–2030 Strategic Consulting Service Contract and the Strategy Mobilization Meeting of Newland Pharmaceutical were grandly held at the company's multifunctional hall. Mr. Xie Jianzhong, Chairman of the company, signed the contract on site with Mr. Duan Jidong, Chairman of Shidai Fanglue, a renowned pharmaceutical strategic consulting and hands-on expert in China. Mr. Zhang Luwei, General Manager of the company, and Mr. Duan Jidong delivered speeches respectively. More than 200 attendees joined the meeting, including Professor Liu Hongmin, Chief Scientist of the company, the expert team of Shidai Fanglue, HR expert consultants, and management personnel at supervisor level and above from the headquarters and the group's Beijing and Zhengzhou branches.  The meeting marked the launch of a strategic consulting program spanning three years and two months (the "2+3" program), implementing the company's 2025–2030 strategy (the "3+3" strategy). Leveraging the diverse advantages brought by its successful IPO, the company will accelerate its journey to become a new leader in the pharmaceutical industry — standing in a new era, seizing new opportunities, achieving new leaps, and creating a new horizon — to realize at an early date the vision of building a first-rate, world-advanced biopharmaceutical enterprise.

  In his speech, General Manager Mr. Zhang Luwei extended a sincere welcome to the expert team of Shidai Fanglue and expressed full confidence in the partnership between the two parties. He noted that over the past nineteen years, under the leadership of the Chairman, all employees of the company have worked as one, persevered with unremitting effort, and overcome numerous difficulties and challenges, achieving outstanding results in corporate development, employee income, shareholder returns, and social contribution. During the pandemic of 2022, the company achieved a successful IPO against the headwind, ushering the company into a brand-new era of development. Today, all employees are full of confidence and drive, and hold high expectations for the company's bright future. At the same time, we are keenly aware of the severe situation facing the domestic and international economic landscape and the pharmaceutical industry. To achieve rapid, steady and sustainable development, beyond a mindset of never resting on past achievements and resetting performance to zero, correctly choosing Newland's development path for the new era and precisely formulating a scientific and sound development strategy are the cornerstone for realizing the company's grand strategic goals in the new era. We firmly believe that through the strong cooperation between Newland and Shidai Fanglue, our goals will surely be accomplished.

  Consulting expert Mr. Cheng Jianjun presented the company and the cooperation project. Beijing Shidai Fanglue Management Consulting Co., Ltd. (hereinafter referred to as "Shidai Fanglue"), founded in 2000, has dedicated more than twenty years to management consulting for the pharmaceutical industry, committed to becoming a professional brand in China's pharmaceutical consulting and a leading think tank for the transformation and development of China's pharmaceutical industry — an idea creator, strategic leader, model innovator, management enhancer and resource integrator for China's pharmaceutical industry. Shidai Fanglue boasts core competitiveness in expert, resource, hands-on, research, brand and service advantages. It excels at rebuilding the capabilities for high-quality development of pharmaceutical enterprises and has successfully served dozens of well-known pharmaceutical companies at home and abroad, delivering notable results and lasting influence in strategy, marketing, group-based management and control, and M&A integration. Drawing on its proven experience in the pharmaceutical industry and in-depth research on industry trends at home and abroad, Shidai Fanglue will fully support Newland Pharmaceutical in formulating and successfully implementing its strategy.

  Mr. Duan Jidong, Chairman of Shidai Fanglue, is a seasoned outstanding entrepreneur and management & consulting expert. As an industry expert, he once attended the symposium held by the State Council Premier, offering suggestions and advice on the development of China's pharmaceutical industry. In his speech, Mr. Duan drew on real corporate development cases from his own experience to illustrate the questions: "What is strategy? What is strategy not? What can strategy solve?" He particularly emphasized that, amid the rapid transformation of policies, markets, technology and products, the height, depth, breadth and practical implementation of a company's strategy are of paramount importance. To formulate strategy well, a company must first make sound top-level design — neither developing blindly and falling into traps, nor hesitating and missing opportunities. Enterprise development should respect science, follow policies, leverage corporate flexibility, study opportunities, and seize them. In his keynote speech themed "Ice and Fire," Mr. Duan traced the development history of China's pharmaceutical industry through five phases. As a participant and firsthand witness, he analyzed how renowned pharmaceutical companies achieved success or failure in each phase through different strategic choices of direction and path, offering important reference and insight for Newland's strategy formulation. Facing the deep adjustment of the pharmaceutical industry, which is currently in the "systemic innovation dividend cycle" phase, Mr. Duan stated that opportunities outweigh challenges — at any time, there are enterprises that rise against the trend, seize their own opportunities and achieve strategic success; the cases are numerous. In conclusion, Mr. Duan expressed that he was greatly inspired by the spirit of Newland people — fearless in the face of difficulties, high-spirited, energetic, driven and fully confident. By stepping beyond the original success model, seeing through trends, breaking cognitive ceilings, unifying thoughts and acting with one heart, they will surely create yet another new world.

  Chairman Mr. Xie Jianzhong affectionately reviewed the company's entrepreneurial journey. Over decades, weathering the Asian and global financial and economic crises, domestic macro-control, changing industry policies and fierce market and product competition, Newland people have always upheld the corporate spirit of "Unity, Diligence, Pragmatism, Enterprise, Pioneering, Innovation, Efficiency and Harmony" — never admitting defeat, never giving up, and tackling difficulties head-on. On the foundation of a bankrupt enterprise, they built a listed company with a solid standing in the industry. Drawing on several unforgettable moments in the company's development history, he explained to the attending experts, point by point, the company's vision, mission, corporate spirit and culture. At the moments of greatest resonance, he received warm rounds of applause, giving the experts and all employees a deeper appreciation of Newland people's image as responsible, tenacious, pragmatic and science-driven.

  Recalling the past, Chairman Xie noted that the company's achievements today were by no means easy. He stated that, in the next step, the company will engage in in-depth discussions with the experts of Shidai Fanglue on implementing the "Six Hundred" Strategy, jointly building new quality productive forces, fostering a sound corporate ecosystem, and achieving the company's sustainable development in the new era. Within the new 2025–2030 strategic planning cycle, the company will consolidate and strengthen its foundational intermediates and API businesses while advancing into the formulation business, forming a dual-driven growth model. The goal is to become a new pharmaceutical leader that is future-oriented, continuously competitive, differentiated in niche markets, and seamlessly connected across domestic and international markets. At the same time, leveraging new synthetic biology technologies, the company will develop advantageous industries including biopharmaceuticals, modern traditional Chinese medicine, and new materials.

  Facing the new changes and transformations of the times, we will strive to uncover the enormous potential market opportunities within them. Leveraging the platform advantages of the company's successful listing, and with a hundredfold of confidence and effort, we will roll up our sleeves and work with all our might, to realize at an early date the vision of building a first-rate, world-advanced biopharmaceutical enterprise!